Arcutis Biotherapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Arcutis Biotherapeutics (ARQT).

Price Target Range — 13 Quarters

Analyst Consensus — 10 Analysts

8Buy

2Hold

Consensus RatingBuy# Analysts10Avg. Consensus PT$31Upside to Avg. PT-2.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 19, 2026	Guggenheim	Seamus Fernandez	PT Raise	Buy	$38→$44
Oct 15, 2026	Cantor Fitzgerald	Steve Seedhouse	Initiate	Overweight	$48
Aug 6, 2026	Morgan Stanley	Vikram Purohit	PT Raise	Overweight	$34→$38
Aug 6, 2026	Guggenheim	Seamus Fernandez	PT Raise	Buy	$35→$38
Aug 6, 2026	Needham	Serge Belanger	PT Raise	Buy	$36→$40
May 7, 2026	Needham	Serge Belanger	Maintained	Buy	$36
Mar 2, 2026	Mizuho	Uy Ear	PT Cut	Outperform	$37→$35
Feb 27, 2026	Guggenheim	Seamus Fernandez	PT Raise	Buy	$34→$35
Feb 26, 2026	TD Cowen	Tyler Van Buren	PT Raise	Buy	$30→$35
Feb 26, 2026	HC Wainwright & Co.	Douglas Tsao	PT Raise	Buy	$30→$34
Feb 26, 2026	Needham	Serge Belanger	PT Raise	Buy	$31→$36
Jan 26, 2026	Needham	Serge Belanger	PT Raise	Buy	$30→$31
Nov 28, 2025	Mizuho	Uy Ear	PT Raise	Outperform	$32→$37
Oct 30, 2025	Goldman Sachs	Richard Law	PT Raise	Neutral	$19→$29
Oct 28, 2025	Needham	Serge Belanger	PT Raise	Buy	$22→$30
Aug 7, 2025	Needham	Serge Belanger	PT Raise	Buy	$20→$22
Jul 25, 2025	Goldman Sachs	Richard Law	Initiate	Neutral	$18
May 23, 2025	Needham	Serge Belanger	Maintained	Buy	$20
Apr 9, 2025	Needham	Serge Belanger	Maintained	Buy	$20
Apr 3, 2025	Guggenheim	Seamus Fernandez	Maintained	Buy	—

Analyst Ratings News

PRO
Guggenheim Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $44

Guggenheim analyst Seamus Fernandez maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $38 to $44.

Benzinga Newsdesk

Why Is Arcutis Biotherapeutics Stock Surging Thursday?

Cantor Fitzgerald initiated Arcutis (ARQT) at Overweight with a $48 target, citing Zoryve's potential for $3.5B in peak sales.

Vandana Singh

PRO
Cantor Fitzgerald Initiates Coverage On Arcutis Biotherapeutics with Overweight Rating, Announces Price Target of $48

Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Arcutis Biotherapeutics (NASDAQ:ARQT) with a Overweight rating and announces Price Target of $48.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Arcutis Biotherapeutics, Raises Price Target to $38

Morgan Stanley analyst Vikram Purohit maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Overweight and raises the price target from $34 to $38.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $38

Guggenheim analyst Seamus Fernandez maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $35 to $38.

Benzinga Newsdesk

PRO
Needham Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $40

Needham analyst Serge Belanger maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $36 to $40.

Benzinga Newsdesk

Arcutis Biotherapeutics Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Arcutis Biotherapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Guggenheim Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $44

Why Is Arcutis Biotherapeutics Stock Surging Thursday?

PRO
Cantor Fitzgerald Initiates Coverage On Arcutis Biotherapeutics with Overweight Rating, Announces Price Target of $48

PRO
Morgan Stanley Maintains Overweight on Arcutis Biotherapeutics, Raises Price Target to $38

PRO
Guggenheim Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $38

PRO
Needham Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $40

People Also Watch

People Also Watch

Arcutis Biotherapeutics Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Arcutis Biotherapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROGuggenheim Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $44

Why Is Arcutis Biotherapeutics Stock Surging Thursday?

PROCantor Fitzgerald Initiates Coverage On Arcutis Biotherapeutics with Overweight Rating, Announces Price Target of $48

PROMorgan Stanley Maintains Overweight on Arcutis Biotherapeutics, Raises Price Target to $38

PROGuggenheim Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $38

PRONeedham Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $40

People Also Watch

People Also Watch

PRO
Guggenheim Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $44

PRO
Cantor Fitzgerald Initiates Coverage On Arcutis Biotherapeutics with Overweight Rating, Announces Price Target of $48

PRO
Morgan Stanley Maintains Overweight on Arcutis Biotherapeutics, Raises Price Target to $38

PRO
Guggenheim Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $38

PRO
Needham Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $40